These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 15157004)

  • 1. Review of health economics modelling in rheumatoid arthritis.
    Emery P
    Pharmacoeconomics; 2004; 22(2 Suppl 1):55-69. PubMed ID: 15157004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis.
    Doan QV; Chiou CF; Dubois RW
    J Manag Care Pharm; 2006 Sep; 12(7):555-69. PubMed ID: 16981801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists.
    Bansback NJ; Regier DA; Ara R; Brennan A; Shojania K; Esdaile JM; Anis AH; Marra CA
    Drugs; 2005; 65(4):473-96. PubMed ID: 15733011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models.
    Heather EM; Payne K; Harrison M; Symmons DP
    Pharmacoeconomics; 2014 Feb; 32(2):109-34. PubMed ID: 24338344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
    Brennan A; Bansback N; Nixon R; Madan J; Harrison M; Watson K; Symmons D
    Rheumatology (Oxford); 2007 Aug; 46(8):1345-54. PubMed ID: 17562686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
    Clark W; Jobanputra P; Barton P; Burls A
    Health Technol Assess; 2004 May; 8(18):iii-iv, ix-x, 1-105. PubMed ID: 15130461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis.
    Spalding JR; Hay J
    Pharmacoeconomics; 2006; 24(12):1221-32. PubMed ID: 17129076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
    Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
    Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of TNF-alpha-blocking agents in the treatment of rheumatoid arthritis.
    Merkesdal S; Ruof J; Mittendorf T; Zeidler H
    Expert Opin Pharmacother; 2004 Sep; 5(9):1881-6. PubMed ID: 15330726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis.
    Nuijten MJ; Engelfriet P; Duijn K; Bruijn G; Wierz D; Koopmanschap M
    Pharmacoeconomics; 2001; 19(10):1051-64. PubMed ID: 11735673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etanercept: a pharmacoeconomic review of its use in rheumatoid arthritis.
    Lyseng-Williamson KA; Plosker GL
    Pharmacoeconomics; 2004; 22(16):1071-95. PubMed ID: 15524495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis.
    Lyseng-Williamson KA; Foster RH
    Pharmacoeconomics; 2004; 22(2):107-32. PubMed ID: 14731052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis.
    Tanno M; Nakamura I; Ito K; Tanaka H; Ohta H; Kobayashi M; Tachihara A; Nagashima M; Yoshino S; Nakajima A
    Mod Rheumatol; 2006; 16(2):77-84. PubMed ID: 16633926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis.
    Moreland LW
    Pharmacoeconomics; 2004; 22(2 Suppl 1):39-53. PubMed ID: 15157003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany.
    Beresniak A; Baerwald C; Zeidler H; Krüger K; Neubauer AS; Dupont D; Merkesdal S
    Clin Exp Rheumatol; 2013; 31(3):400-8. PubMed ID: 23464803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry.
    Cárdenas M; de la Fuente S; Font P; Castro-Villegas M; Romero-Gómez M; Ruiz-Vílchez D; Calvo-Gutiérez J; Escudero-Contreras A; Casado M; Del Prado J; Collantes-Estévez E
    Rheumatol Int; 2016 Feb; 36(2):231-41. PubMed ID: 26494567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients.
    Benucci M; Li Gobbi F; Sabadini L; Saviola G; Baiardi P; Manfredi M
    Int J Immunopathol Pharmacol; 2009; 22(4):1147-52. PubMed ID: 20074482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current aspects of cost effectiveness of TNF-alpha blocking agents in patients with rheumatoid arthritis].
    Merkesdal S; Ruof J
    Z Rheumatol; 2002; 61 Suppl 2():II/29-32. PubMed ID: 12491120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An economic approach to health care.
    Homik JE; Suarez-Almazor M
    Best Pract Res Clin Rheumatol; 2004 Apr; 18(2):203-18. PubMed ID: 15121040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The issue of comparators in economic evaluations of biologic response modifiers in rheumatoid arthritis.
    Tsao NW; Bansback NJ; Shojania K; Marra CA
    Best Pract Res Clin Rheumatol; 2012 Oct; 26(5):659-76. PubMed ID: 23218430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.